Adaptimmune Therapeutics plc (473A) — Capital Reinvestment Ratio

Latest as of June 2024: 0.02x

Adaptimmune Therapeutics plc (473A) has a Capital Reinvestment Ratio of 0.02x as of June 2024, meaning it reinvests 0% of its operating cash flow (€47.40 Million) in capital expenditures (€754.00K). See how much free cash does Adaptimmune Therapeutics plc generate to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

0.02x

Capex / Operating Cash Flow

Operating Cash Flow

€47.40 Million

EUR

Capital Expenditures

€754.00K

EUR

Data as of

Jun 2024

Most recent filing

Adaptimmune Therapeutics plc Capital Reinvestment Ratio (2021–2021)

This chart tracks Adaptimmune Therapeutics plc's Capital Reinvestment Ratio across 1 annual periods.

Annual Capital Reinvestment Ratio for Adaptimmune Therapeutics plc (2021–2021)

Year-by-year Capital Reinvestment Ratio for Adaptimmune Therapeutics plc from 2021 to 2021. For live market cap and broader valuation context, see Adaptimmune Therapeutics plc (473A) total market value.

Year	Reinvestment Ratio	Operating CF (EUR)	Capital Expenditures	YoY Change
2021	0.80x	€10.73 Million	€8.57 Million	—

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow